510(k) vs De Novo Classification: Which Pathway for Your Medical Device
The 510(k) pathway requires demonstrating substantial equivalence to a legally marketed predicate device and is the fastest route for devices with existing predicates. The De Novo pathway is for novel, low-to-moderate risk devices that have no predicate and would otherwise default to Class III. The 510(k) has a 90-day statutory review clock; De Novo has a 150-day review commitment under MDUFA V. Choosing the wrong pathway wastes months. If a predicate exists, use 510(k). If your device is novel with no predicate and presents low-to-moderate risk, use De Novo.
Key Takeaways
Key Takeaways
- Use 510(k) when a legitimate predicate device exists with the same intended use; use De Novo when your device is novel with no predicate and presents low-to-moderate risk.
- 510(k) has a 90-day statutory review clock; De Novo has a 150-review-day performance goal under MDUFA V.
- A successful De Novo creates a new product classification and becomes a predicate for future 510(k) submissions, creating a strategic first-mover advantage.
- Filing a 510(k) with a weak or mismatched predicate wastes months — a Pre-Submission meeting with FDA is strongly recommended for borderline cases.
The Classification Framework
FDA classifies medical devices into three regulatory classes based on the level of control necessary to provide reasonable assurance of safety and effectiveness:
| Class | Risk Level | Controls | Premarket Pathway |
|---|---|---|---|
| Class I | Lowest | General controls only | Most exempt from premarket review; some require 510(k) |
| Class II | Moderate | General controls + special controls | 510(k) or De Novo |
| Class III | Highest | General controls + premarket approval | PMA |
When a new device type has no existing classification, it is automatically designated Class III under Section 513(f)(1) of the FD&C Act. This automatic Class III designation triggers two options:
- Submit a PMA: Full premarket approval application with clinical evidence of safety and effectiveness
- Submit a De Novo request: Request reclassification to Class I or Class II if the device presents low-to-moderate risk
The De Novo pathway exists specifically to prevent novel, low-to-moderate risk devices from being forced through the PMA process simply because no predicate exists.
The 510(k) Pathway
Legal Basis
Section 510(k) of the FD&C Act requires manufacturers to submit a premarket notification to FDA at least 90 days before marketing a Class I (non-exempt) or Class II device. FDA reviews the notification to determine whether the new device is substantially equivalent (SE) to one or more legally marketed predicate devices.
Substantial Equivalence
Substantial equivalence does not mean identical. A device is substantially equivalent to a predicate if:
- It has the same intended use as the predicate, AND
- It has the same technological characteristics as the predicate, OR
- It has different technological characteristics but the information submitted demonstrates that the device is as safe and effective as the predicate and does not raise different questions of safety and effectiveness
The substantial equivalence determination follows a structured algorithm described in FDA's guidance "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications" (July 2014).
510(k) Submission Types
| Type | When Used | Review Path |
|---|---|---|
| Traditional 510(k) | Standard submissions | Full FDA review |
| Special 510(k) | Device modifications by original holder or subsequent submitter | Abbreviated review, relies on design controls |
| Abbreviated 510(k) | Conformance to recognized standards or FDA guidance | Relies on declarations of conformity |
510(k) Submission Content
Per 21 CFR 807.87 and FDA's "Refuse to Accept Policy for 510(k)s" guidance (2022):
| Section | Content |
|---|---|
| Cover letter | Submission type, device name, contact information |
| Device description | Detailed description of the device, including components, materials, specifications |
| Intended use / Indications for use | FDA Form 3881 |
| Predicate comparison | Side-by-side comparison of technological characteristics and intended use |
| Substantial equivalence discussion | Argument for SE, addressing similarities and differences |
| Performance testing | Bench testing, biocompatibility (if applicable), software testing, clinical data (if needed) |
| Labeling | Draft labels, instructions for use, package insert |
| Sterilization (if applicable) | Sterilization validation data |
| Biocompatibility (if applicable) | Per ISO 10993, FDA guidance |
| Software documentation (if applicable) | Per "Content of Premarket Submissions for Device Software Functions" |
| 510(k) summary or statement | Required under 21 CFR 807.92 or 807.93 |
510(k) Review Timeline
| Phase | Duration | Notes |
|---|---|---|
| FDA acceptance review | 15 calendar days | RTA (Refuse to Accept) check |
| Substantive review | 90 FDA days (statutory) | Clock pauses during AI requests |
| Additional Information (AI) request | Variable (30-90+ days) | Common; pauses the review clock |
FDA's MDUFA V performance goals include review metrics for 510(k) submissions, but actual elapsed time can vary when FDA issues requests for additional information.
510(k) Decision Outcomes
| Decision | Meaning |
|---|---|
| Substantially Equivalent (SE) | Device may be marketed; subject to general and special controls for its classification |
| Not Substantially Equivalent (NSE) | Device cannot be marketed via 510(k); must pursue De Novo, PMA, or modify the device |
| Additional Information (AI) | FDA needs more information before making a decision; review clock pauses |
| Withdrawal | Submitter withdraws the 510(k) before a decision |
The De Novo Pathway
Legal Basis
Section 513(f)(2) of the FD&C Act, as amended by the FDA Reauthorization Act of 2017 (FDARA), allows a manufacturer to submit a De Novo classification request directly to FDA for a novel device that the manufacturer believes is appropriate for Class I or Class II classification. Prior to FDARA, De Novo requests could only be submitted after receiving a Not Substantially Equivalent (NSE) determination on a 510(k). The current pathway allows direct De Novo submission without a prior 510(k).
When De Novo Is Appropriate
The De Novo pathway is appropriate when all of the following conditions are met:
- The device has no legally marketed predicate (no substantially equivalent device exists)
- The device presents low-to-moderate risk (appropriate for Class I or II, not Class III)
- General controls alone (Class I) or general controls plus special controls (Class II) are sufficient to provide reasonable assurance of safety and effectiveness
De Novo Submission Content
Per FDA's guidance "De Novo Classification Process (Evaluation of Automatic Class III Designation)" (October 2021):
| Section | Content |
|---|---|
| Device description | Detailed description including principles of operation, technological characteristics |
| Intended use / Indications for use | Specific clinical use, target population, use environment |
| Proposed classification | Class I or Class II, with justification |
| Proposed product code | Suggested product code and device classification name |
| Regulatory history | Prior 510(k) or pre-submission history (if any) |
| Risk/benefit analysis | Comprehensive analysis of known and foreseeable risks vs. benefits |
| Proposed special controls (Class II) | Specific controls that mitigate identified risks |
| Non-clinical testing | Performance testing demonstrating safety and effectiveness |
| Clinical evidence | Clinical data supporting safety and effectiveness (when needed) |
| Labeling | Proposed labeling including contraindications, warnings, directions for use |
| Software documentation | Per FDA software guidance (if software device) |
| Cybersecurity | Per FDA cybersecurity guidance (if applicable) |
Special Controls
When FDA grants a De Novo request for Class II classification, the De Novo order includes Special Controls. These are legally binding requirements that apply to the specific device type and become the standard for future 510(k) submissions using the De Novo decision as a predicate.
Special Controls can include:
| Type | Examples |
|---|---|
| Performance standards | Minimum sensitivity/specificity, accuracy requirements |
| Design controls | Specific design verification and validation requirements |
| Labeling requirements | Mandatory label content, warnings, contraindications |
| Post-market requirements | Post-market surveillance studies, annual reporting |
| Patient registry | Enrollment in a patient registry |
| Clinical testing | Pre-specified clinical testing protocols for future applicants |
De Novo Review Timeline
| Phase | Duration | Notes |
|---|---|---|
| FDA acceptance review | 15 calendar days | Completeness check |
| Substantive review | 150 review days (MDUFA V) | Longer than 510(k) due to novel device evaluation |
| Additional Information (AI) request | Variable (30-120+ days) | Common; pauses the review clock |
FDA's MDUFA V performance goals commit to completing 70% of De Novo reviews within 150 FDA review days.
De Novo Decision Outcomes
| Decision | Meaning |
|---|---|
| Granted | Device classified as Class I or II; De Novo order issued with classification and Special Controls |
| Denied | Device not appropriate for Class I or II; must pursue PMA |
| Withdrawal | Manufacturer withdraws the request before decision |
Head-to-Head Comparison
Submission Requirements
| Element | 510(k) | De Novo |
|---|---|---|
| Predicate device required | Yes | No |
| Substantial equivalence argument | Yes | No |
| Risk/benefit analysis | Not explicitly required | Required |
| Special controls proposal | No (uses existing) | Yes (manufacturer proposes) |
| Clinical data | Often not required (depends on device) | More commonly required (novel device) |
| Software documentation | If software device | If software device |
| Cybersecurity documentation | If applicable | If applicable |
Process Comparison
| Factor | 510(k) | De Novo |
|---|---|---|
| FDA review days | 90 (statutory) | 150 (MDUFA V commitment) |
| User fee (FY 2026) | $26,067 standard / $6,517 small business | $173,782 standard / $43,446 small business |
| FDA decision | SE / NSE | Granted / Denied |
| Creates new classification | No | Yes (new product code and regulation number) |
| Establishes predicate | Yes (for future 510(k)s) | Yes (becomes predicate for future 510(k)s) |
Strategic Comparison
| Consideration | 510(k) | De Novo |
|---|---|---|
| Speed to market | Faster | Slower |
| Regulatory certainty | Higher (established classification) | Lower (novel assessment) |
| Competitive barrier | Lower (predicate available to competitors) | Higher (you define the Special Controls) |
| Flexibility in intended use | Constrained by predicate's intended use | Greater (you define the intended use) |
| Clinical evidence burden | Often lower | Often higher |
| Post-market requirements | Per existing Special Controls | Per De Novo order (you help shape them) |
Pathway Selection Decision Tree
Step 1: Does a Predicate Exist?
Search FDA's databases (Product Classification, 510(k), De Novo, PMA) for legally marketed devices with the same or similar intended use and technological characteristics.
If yes: Proceed to Step 2.
If no: Proceed to Step 3.
Step 2: Is the Device Substantially Equivalent?
Evaluate whether the device has the same intended use and same or similar technological characteristics as the predicate. Consider:
- Is the intended use identical to or a subset of the predicate's intended use?
- Are the technological characteristics similar enough that differences do not raise new safety/effectiveness questions?
- Can performance testing demonstrate that the device is at least as safe and effective as the predicate?
If yes: Use 510(k).
If no: The device may need De Novo (if no other predicate is available) or the manufacturer may need to identify a different predicate.
Step 3: Is the Device Low-to-Moderate Risk?
Evaluate whether general controls alone (Class I) or general controls plus special controls (Class II) can provide reasonable assurance of safety and effectiveness.
If yes: Use De Novo.
If no: The device likely requires PMA (Class III).
Step 4: Pre-Submission Confirmation
For borderline cases, file a Pre-Submission (Q-Sub) with FDA to confirm the appropriate pathway. This is strongly recommended when:
- The predicate comparison is borderline (technological differences exist)
- The device incorporates novel technology (AI/ML, new sensor technology)
- The intended use differs from available predicates
- Clinical evidence requirements are unclear
Recent Trends in De Novo Decisions
Growth in De Novo Submissions
De Novo submissions have increased significantly since the direct submission pathway was established by FDARA in 2017:
| Year | De Novo Requests Received | Granted | Denied/Withdrawn |
|---|---|---|---|
| 2017 | ~30 | ~20 | ~10 |
| 2018 | ~40 | ~25 | ~15 |
| 2019 | ~50 | ~35 | ~15 |
| 2020 | ~65 | ~45 | ~20 |
| 2021 | ~80 | ~50 | ~30 |
| 2022 | ~100 | ~60 | ~40 |
| 2023 | ~120 | ~70 | ~50 |
| 2024 | ~140 | ~80 | ~60 |
Note: These are approximate figures based on publicly available FDA data. Exact numbers may vary.
De Novo for Digital Health
A significant proportion of recent De Novo grants have been for digital health and AI/ML-enabled devices. Product codes created through De Novo for digital health include:
| Product Code | Device Type | Year Created |
|---|---|---|
| QAS | Radiological computer-aided triage and notification | 2018 |
| QMT | Prescription cognitive behavioral therapy device | 2017 |
| QPN | Genetic health risk assessment system | 2017 |
| QRZ | ECG software for over-the-counter use | 2018 |
| QJU | AI-based radiological CADe for lung nodules | 2020 |
| QND | Virtual reality-based chronic pain therapeutic | 2021 |
Each of these De Novo decisions created a new product classification that subsequent manufacturers can use as a predicate for 510(k) submissions.
Common Mistakes in Pathway Selection
Mistake 1: Filing 510(k) with an Inappropriate Predicate
Using a predicate with a different intended use or fundamentally different technology leads to NSE determinations and wasted review time. A predicate must have the same intended use. "Similar" is not sufficient.
Mistake 2: Filing 510(k) When De Novo Is Required
If no legitimate predicate exists, forcing a 510(k) with a weak predicate comparison will result in an NSE determination or significant FDA pushback. It is better to file De Novo directly than to file a 510(k) that will fail.
Mistake 3: Filing De Novo When a Predicate Exists
De Novo takes longer and requires more evidence than 510(k). If a legitimate predicate exists, using 510(k) is faster and less resource-intensive.
Mistake 4: Underestimating De Novo Evidence Requirements
De Novo submissions for novel devices frequently require clinical data, even when the manufacturer believes bench testing is sufficient. Discuss evidence requirements with FDA in a Pre-Submission meeting before investing in the wrong testing strategy.
Mistake 5: Ignoring the Pre-Submission Process
For either pathway, a Pre-Submission meeting can save months of delay by aligning on pathway selection, predicate choice, evidence requirements, and Special Controls (for De Novo) before the submission is filed.
Practical Considerations
Cost Comparison
FDA user fees are published annually and are only one part of submission cost. Total spend depends heavily on testing scope, clinical evidence needs, software documentation, and whether the device requires iterative interaction with FDA.
From De Novo to 510(k): The Lifecycle
A successful De Novo creates a new classification and product code. This De Novo decision then serves as a predicate for future 510(k) submissions, both by the original manufacturer (for device modifications) and by competitors entering the same market.
This creates a strategic dynamic:
- First-to-market via De Novo: Higher cost and time investment, but you define the classification and Special Controls
- Follow-on via 510(k): Lower cost and faster timeline, but must demonstrate substantial equivalence to the De Novo device and comply with the Special Controls you did not choose
Key Regulatory References
| Document | Source | Year |
|---|---|---|
| The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications | FDA | 2014 |
| Refuse to Accept Policy for 510(k)s | FDA | 2022 |
| De Novo Classification Process (Evaluation of Automatic Class III Designation) | FDA | 2021 |
| Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program | FDA | 2023 |
| MDUFA V Commitment Letter | FDA | 2022 |
| 21 CFR 807 Subpart E (Premarket Notification Procedures) | FDA | Current |
| Section 513(f)(2) FD&C Act (De Novo Classification) | U.S. Code | Current |
References
Sources
- Refuse to Accept Policy for 510(k)s | FDA
- De Novo Classification Process (Evaluation of Automatic Class III Designation) | FDA
- De Novo Classification Request | FDA
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program | FDA
- Medical Device User Fee Amendments (MDUFA): Fees | FDA
- 21 CFR Part 807, Subpart E | eCFR
- 21 U.S.C. 360c(f)(2) | Legal Information Institute